We are live on
!
Find out more
CWM
CIBC World Markets Portfolio holdings
AUM
$20.8B
This Fund
S&P 500
This Quarter
Est. Return
-3.31%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$12.7B
AUM Growth
-$4.36B
(-26%)
Cap. Flow
-$3.8B
Cap. Flow
% of AUM
-29.89%
Top 10 Holdings %
Top 10 Hldgs %
38.21%
Holding
1,893
New
568
Increased
757
Reduced
513
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$211M |
| 2 |
Crown Castle
CCI
|
+$52.2M |
| 3 |
Tesla
TSLA
|
+$46.6M |
| 4 |
XP
XP
|
+$25.2M |
| 5 |
Electronic Arts
EA
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$587M |
| 2 |
Honeywell
HON
|
+$142M |
| 3 |
Mastercard
MA
|
+$126M |
| 4 |
Apple
AAPL
|
+$111M |
| 5 |
Meta Platforms (Facebook)
META
|
+$111M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.12% |
| 2 | Financials | 11.86% |
| 3 | Consumer Discretionary | 10.19% |
| 4 | Communication Services | 9.97% |
| 5 | Healthcare | 7.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Lineage Cell Therapeutics
LCTX
$282M
| $18K | ﹤0.01% |
39,837
+26,012
| +188% | +$15.3K |
|
1802
Fate Therapeutics
FATE
$287M
| $17.6K | ﹤0.01% |
+22,214
| New | +$27.2K |
|
1803
MacroGenics
MGNX
$248M
| $17.3K | ﹤0.01% |
+13,639
| New | +$35.6K |
|
1804
Pliant Therapeutics
PLRX
$65.6M
| $17.1K | ﹤0.01% |
+12,644
| New | +$76.8K |
|
1805
Caribou Biosciences
CRBU
$159M
| $16.7K | ﹤0.01% |
+18,255
| New | +$23.7K |
|
1806
Energy Vault
NRGV
$540M
| $16.4K | ﹤0.01% |
+23,522
| New | +$36.1K |
|
1807
Destination XL Group
DXLG
$31M
| $16.3K | ﹤0.01% |
+11,135
| New | +$26K |
|
|
VTYX
1808
DELISTED
Ventyx Biosciences
VTYX
| $15.5K | ﹤0.01% |
+13,485
| New | +$23.2K |
|
1809
SES AI
SES
$189M
| $15.3K | ﹤0.01% |
29,416
+17,228
| +141% | +$15.8K |
|
|
FRGE
1810
DELISTED
Forge Global Holdings
FRGE
| $14.7K | ﹤0.01% |
1,741
+1,014
| +139% | +$11.7K |
|
1811
Tango Therapeutics
TNGX
$4.71B
| $14.5K | ﹤0.01% |
+10,586
| New | +$26K |
|
1812
Rekor Systems
REKR
$91.6M
| $14.5K | ﹤0.01% |
+16,351
| New | +$25.8K |
|
1813
Zura Bio
ZURA
$538M
| $14.4K | ﹤0.01% |
+11,200
| New | +$17.7K |
|
1814
Veru
VERU
$37.2M
| $14.4K | ﹤0.01% |
2,931
+1,695
| +137% | +$10.5K |
|
1815
Chegg
CHGG
$90.7M
| $14.3K | ﹤0.01% |
+22,344
| New | +$27.7K |
|
|
LNAI
1816
Lunai Bioworks
LNAI
$11M
| $13.7K | ﹤0.01% |
315
+180
| +133% | +$11.5K |
|
1817
GrowGeneration
GRWG
$89.5M
| $13.4K | ﹤0.01% |
+12,418
| New | +$16.7K |
|
|
NOTE
1818
DELISTED
FiscalNote
NOTE
| $13.3K | ﹤0.01% |
+1,368
| New | +$20.6K |
|
1819
Sutro Biopharma
STRO
$403M
| $11.8K | ﹤0.01% |
+1,816
| New | +$28.6K |
|
1820
Stem
STEM
$51.7M
| $11.8K | ﹤0.01% |
1,684
+974
| +137% | +$11.3K |
|
1821
Lexicon Pharmaceuticals
LXRX
$1.06B
| $11.7K | ﹤0.01% |
25,477
+14,733
| +137% | +$9.29K |
|
|
KG
1822
Kestrel Group
KG
$73.9M
| $11.3K | ﹤0.01% |
+993
| New | +$18.7K |
|
1823
LiveOne
LVO
$60.5M
| $11.3K | ﹤0.01% |
+1,614
| New | +$15.9K |
|
|
INZY
1824
DELISTED
Inozyme Pharma
INZY
| $10.8K | ﹤0.01% |
+11,913
| New | +$16.5K |
|
1825
Pyxis Oncology
PYXS
$211M
| $10.7K | ﹤0.01% |
+10,945
| New | +$14.6K |
|
Similar funds
VRS
FAF
BGIM
CIM
PPFA
GRP
UOC
CIBC World Markets's Q1 2025 Portfolio in Review
As of Q1 2025, CIBC World Markets held 1,893 positions worth $12.7B, down 26% from $17.1B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
CIBC World Markets withdrew a net $3.8B in Q1 2025, closing 51 positions and reducing 513 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $41M position sold in full.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 29% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, CIBC World Markets opened a new position in XP worth $25.2M.
- CIBC World Markets's largest Q1 2025 buy was XP: 1,832,600 shares worth $25.2M.
- CIBC World Markets added most to Microsoft in Q1 2025, an estimated $211M increase.
- CIBC World Markets's biggest Q1 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $587M.
- CIBC World Markets fully exited Apellis Pharmaceuticals in Q1 2025, selling an estimated $41M.
- CIBC World Markets's ten largest holdings make up 38% of its $12.7B portfolio in Q1 2025.
- CIBC World Markets opened 568 new positions and closed 51 in Q1 2025.
- CIBC World Markets's portfolio value fell 26% quarter-over-quarter to $12.7B.
Based on CIBC World Markets's 13F filing for Q1 2025, filed 13 May 2025.